-
FDA warnings for existing drugs dominate pharmaceutical news this month.
-
Serum analysis of 45 subjects for antibodies and humoral immunity over a median of 15 years showed antiviral responses ranging from 11-19 years for tetanus-diphtheria, 50 years for varicella-zoster, and up to 200 years for measles and mumps.
-
The FDA has approved a non-halogenated nasal steroid for use in pediatric patients aged 6 to 12 years and adults. Ciclesonide is a prodrug that was previously approved for adults and adolescents but was not marketed. It's to be marketed by Nycomed US Inc. as Omnaris.
-
-
Human Papillomavirus (HPV) testing has proved efficacious in triaging minimally abnormal cytology to further investigation or surveillance. However, despite its high sensitivity for cervix pathology, its value as a primary screening technology has been formally evaluated in only a limited way.
-
Last month an article was featured in the OB/GYN Clinical Alert from the October issue of Obstetrics & Gynecology. Since the issue was rich in good material, I will go back to it to review information pertaining to one of the most common questions asked of providers"How much weight should I gain in my pregnancy?"
-
The Collaborative Group on Epidemiological Studies of Cervical Cancer has combined and reanalyzed any relevant data from all epidemiological studies on the association between cervical carcinoma and the pattern of oral contraceptive use.
-
In the November 20th issue of the Journal of Clinical Oncology, two important articles appear, demonstrating the clinical impact of a novel therapeutic, bevacizumab, in women with recurrent ovarian cancer.
-
In this issue: FDA warnings for existing drugs dominate pharmaceutical news this month.
-
